Michel Roberge's Biography

Michel Roberge, Scientific Director, University of British Columbia

Michel Roberge is a Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia in Vancouver, Canada. He is also Scientific Director of the Centre for Drug Research and Development (www.cdrd.ca) and heads CDRD’s Drug Screening Division. He specializes in chemical biology and in the development of cell-based and high content screening assays. His work has led to the identification of small molecules affecting diverse cellular processes and proteins such as autophagy, cancer cell invasion, cell cycle checkpoints, mitotic progression, mitotic slippage, mTOR signaling, protein phosphatases, v-ATPase, indoleamine dioxygenase and the influenza M2 proton channel. He has also recently been involved in the discovery of bioactive small molecules targeting tuberculosis. He is part of a multidisciplinary team that has discovered anticancer agents undergoing preclinical development and the microtubule-targeting drug HTI-286, which reached phase II clinical trial.